View Item 

Show simple item record

Race and Beta‐Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self‐Reported Race and Proportion of African Genetic Ancestry
dc.contributor.authorLuzum, Jasmine A.
dc.contributor.authorPeterson, Edward
dc.contributor.authorLi, Jia
dc.contributor.authorShe, Ruicong
dc.contributor.authorGui, Hongsheng
dc.contributor.authorLiu, Bin
dc.contributor.authorSpertus, John A.
dc.contributor.authorPinto, Yigal M.
dc.contributor.authorWilliams, L. Keoki
dc.contributor.authorSabbah, Hani N.
dc.contributor.authorLanfear, David E.
dc.date.accessioned2018-07-13T15:47:26Z
dc.date.available2019-07-01T14:52:17Zen
dc.date.issued2018-05-15
dc.identifier.citationLuzum, Jasmine A.; Peterson, Edward; Li, Jia; She, Ruicong; Gui, Hongsheng; Liu, Bin; Spertus, John A.; Pinto, Yigal M.; Williams, L. Keoki; Sabbah, Hani N.; Lanfear, David E. (2018). "Race and Beta‐Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self‐Reported Race and Proportion of African Genetic Ancestry." Journal of the American Heart Association (10): n/a-n/a.
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/2027.42/144637
dc.publisherWiley Periodicals, Inc.
dc.subject.otherrace
dc.subject.otherancestry
dc.subject.otherbeta‐blocker
dc.subject.otherdisparity
dc.subject.othergenetics
dc.subject.othergenomics
dc.subject.otherheart failure
dc.subject.otherpharmacogenetics
dc.subject.otherpharmacogenomics
dc.titleRace and Beta‐Blocker Survival Benefit in Patients With Heart Failure: An Investigation of Self‐Reported Race and Proportion of African Genetic Ancestry
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144637/1/jah33167.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144637/2/jah33167_am.pdf
dc.identifier.sourceJournal of the American Heart Association
dc.identifier.citedreferenceWriting Committee Members, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128: e240 – e327.
dc.identifier.citedreferenceGoldstein S, Deedwania P, Gottlieb S, Wikstrand J; MERIT‐HF Study Group. Metoprolol CR/XL in black patients with heart failure (from the metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol. 2003; 92: 478 – 480.
dc.identifier.citedreferenceYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136: e137 – e161.
dc.identifier.citedreferenceTate SK, Goldstein DB. Will tomorrow’s medicines work for everyone? Nat Genet. 2004; 36: S34 – S42.
dc.identifier.citedreferenceTaylor JS, Ellis GR. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. Am J Cardiovasc Drugs. 2002; 2: 389 – 399.
dc.identifier.citedreferenceBeta‐Blocker Evaluation of Survival Trial Investigators. A trial of the beta‐blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001; 344: 1659 – 1667.
dc.identifier.citedreferenceDomanski MJ, Krause‐Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, Murray D, Oren R, Rosenberg Y, Young J, Zile M, Eichhorn E; BEST Investigators. A trial of the beta‐blocker bucindolol in patients with advanced chronic heart failure. J Card Fail. 2003; 9: 354 – 363.
dc.identifier.citedreferenceLanfear DE, Hrobowski TN, Peterson EL, Wells KE, Swadia TV, Spertus JA, Williams LK. Association of beta‐blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail. 2012; 5: 202 – 208.
dc.identifier.citedreferenceCresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW II. Clinical and genetic modifiers of long‐term survival in heart failure. J Am Coll Cardiol. 2009; 54: 432 – 444.
dc.identifier.citedreferenceMersha TB, Abebe T. Self‐reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics. 2015; 9: 1 – 15.
dc.identifier.citedreferenceCresci S, Dorn GW II, Jones PG, Beitelshees AL, Li AY, Lenzini PA, Province MA, Spertus JA, Lanfear DE. Adrenergic‐pathway gene variants influence beta‐blocker‐related outcomes after acute coronary syndrome in a race‐specific manner. J Am Coll Cardiol. 2012; 60: 898 – 907.
dc.identifier.citedreferenceLiggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, Spertus JA, Koch WJ, Kardia SL, Dorn GW II. A GRK5 polymorphism that inhibits beta‐adrenergic receptor signaling is protective in heart failure. Nat Med. 2008; 14: 510 – 517.
dc.identifier.citedreferenceLobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF Jr, Hill JA, Aranda JM Jr, Johnson JA. Synergistic polymorphisms of beta1 and alpha2C‐adrenergic receptors and the influence on left ventricular ejection fraction response to beta‐blocker therapy in heart failure. Pharmacogenet Genomics. 2007; 17: 277 – 282.
dc.identifier.citedreferenceSmall KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1‐ and alpha2C‐adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002; 347: 1135 – 1142.
dc.identifier.citedreferenceSmith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, Kessing BD, Malasky MJ, Scafe C, Le E, De Jager PL, Mignault AA, Yi Z, De The G, Essex M, Sankale JL, Moore JH, Poku K, Phair JP, Goedert JJ, Vlahov D, Williams SM, Tishkoff SA, Winkler CA, De La Vega FM, Woodage T, Sninsky JJ, Hafler DA, Altshuler D, Gilbert DA, O’Brien SJ, Reich D. A high‐density admixture map for disease gene discovery in African Americans. Am J Hum Genet. 2004; 74: 1001 – 1013.
dc.identifier.citedreferenceMcKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285: 1441 – 1446.
dc.identifier.citedreferenceLanfear DE, Peterson E, Wells K, Williams LK. Discharge medication status compares poorly with claims‐based outpatient medication exposure estimates. Circ Cardiovasc Qual Outcomes. 2011; 4: AP234.
dc.identifier.citedreferencePatterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O’Brien SJ, Altshuler D, Daly MJ, Reich D. Methods for high‐density admixture mapping of disease genes. Am J Hum Genet. 2004; 74: 979 – 1000.
dc.identifier.citedreferencePocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN; Meta‐Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013; 34: 1404 – 1413.
dc.identifier.citedreferenceD’Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non‐randomized control group. Stat Med. 1998; 17: 2265 – 2281.
dc.identifier.citedreferenceTalameh JA, Lanfear DE. Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep. 2012; 9: 23 – 32.
dc.identifier.citedreferenceTian C, Gregersen PK, Seldin MF. Accounting for ancestry: population substructure and genome‐wide association studies. Hum Mol Genet. 2008; 17: R143 – R150.
dc.identifier.citedreferenceAbraham WT, Massie BM, Lukas MA, Lottes SR, Nelson JJ, Fowler MB, Greenberg B, Gilbert EM, Franciosa JA; COHERE Participant Physicians. Tolerability, safety, and efficacy of beta‐blockade in black patients with heart failure in the community setting: insights from a large prospective beta‐blocker registry. Congest Heart Fail. 2007; 13: 16 – 21.
dc.identifier.citedreferenceShekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of angiotensin‐converting enzyme inhibitors and beta‐blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta‐analysis of major clinical trials. J Am Coll Cardiol. 2003; 41: 1529 – 1538.
dc.identifier.citedreferenceShah M, Patnaik S, Patel B, Arora S, Patel N, Lahewala S, Figueredo VM, Martinez MW, Jacobs L. The day of the week and acute heart failure admissions: relationship with acute myocardial infarction, 30‐day readmission rate and in‐hospital mortality. Int J Cardiol. 2017; 249: 292 – 300.
dc.identifier.citedreferenceMirkin KA, Enomoto LM, Caputo GM, Hollenbeak CS. Risk factors for 30‐day readmission in patients with congestive heart failure. Heart Lung. 2017; 46: 357 – 362.
dc.identifier.citedreferenceO’Connor M, Murtaugh CM, Shah S, Barron‐Vaya Y, Bowles KH, Peng TR, Zhu CW, Feldman PH. Patient characteristics predicting readmission among individuals hospitalized for heart failure. Med Care Res Rev. 2016; 73: 3 – 40.
dc.identifier.citedreferenceEpstein AM, Jha AK, Orav EJ. The relationship between hospital admission rates and rehospitalizations. N Engl J Med. 2011; 365: 2287 – 2295.
dc.identifier.citedreferenceSpertus JA, Jones PG, Masoudi FA, Rumsfeld JS, Krumholz HM. Factors associated with racial differences in myocardial infarction outcomes. Ann Intern Med. 2009; 150: 314 – 324.
dc.identifier.citedreferenceRathore SS, Foody JM, Wang Y, Smith GL, Herrin J, Masoudi FA, Wolfe P, Havranek EP, Ordin DL, Krumholz HM. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA. 2003; 289: 2517 – 2524.
dc.identifier.citedreferenceBernardez‐Pereira S, Gioli‐Pereira L, Marcondes‐Braga FG, Santos PC, Spina JM, Horimoto AR, Santos HC, Bacal F, Fernandes F, Mansur AJ, Pietrobon R, Krieger JE, Mesquita ET, Pereira AC. Genomic ancestry as a predictor of haemodynamic profile in heart failure. Open Heart. 2016; 3: e000434.
dc.identifier.citedreferenceSchulz A, Israel B, Williams D, Parker E, Becker A, James S. Social inequalities, stressors and self reported health status among African American and white women in the Detroit metropolitan area. Soc Sci Med. 2000; 51: 1639 – 1653.
dc.identifier.citedreferenceThe Cardiac Insufficiency Bisoprolol Study II (CIBIS‐II): a randomised trial. Lancet. 1999; 353: 9 – 13.
dc.identifier.citedreferenceMERIT‐HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT‐HF). Lancet. 1999; 353: 2001 – 2007.
dc.identifier.citedreferencePacker M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann‐Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106: 2194 – 2199.
dc.identifier.citedreferencePacker M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349 – 1355.
dc.identifier.citedreferenceGoldstein S. Beta blocker therapy in African American patients with heart failure. Heart Fail Rev. 2004; 9: 161 – 167.
dc.identifier.citedreferenceRandomised, placebo‐controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet. 1997; 349: 375 – 380.
dc.identifier.citedreferenceWriting Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016; 133: e38 – e60.
dc.identifier.citedreferenceYancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M; U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001; 344: 1358 – 1365.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jah33167.pdf
Size:
421.4KB
Format:
PDF
View/Open
Name:
jah33167_am.pdf
Size:
369.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.